# Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors

> **NCT01632696** · EARLY_PHASE1 · TERMINATED · sponsor: **Peregrine Pharmaceuticals** · enrollment: 11 (actual)

## Conditions studied

- Malignant Solid Tumor

## Interventions

- **DRUG:** I-124 PGN650 for PET/CT

## Key facts

- **NCT ID:** NCT01632696
- **Lead sponsor:** Peregrine Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2017-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01632696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01632696, "Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01632696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*